Table 2 Summary of dose reductions and delays
Characteristic | Number | % |
|---|---|---|
Dose reductions and delays per patient | ||
Number of patients | 39 | |
Dose delays | 24 | 61.5 |
Dose reductions | 11 | 28.2 |
Dose reductions and delays per cycle | ||
Number of cycles | 215 | |
Dose delays | 47 | 21.9 |
Dose reductions | ||
5-Fluorouracil | 33 | 15.3 |
Oxaliplatin | 39 | 18.1 |
Irinotecan | 46 | 21.4 |